NO20041758L - Krystallinsk natriumesalt av telmiseartan og dets anvendelse som angiotensin-antagonist - Google Patents

Krystallinsk natriumesalt av telmiseartan og dets anvendelse som angiotensin-antagonist

Info

Publication number
NO20041758L
NO20041758L NO20041758A NO20041758A NO20041758L NO 20041758 L NO20041758 L NO 20041758L NO 20041758 A NO20041758 A NO 20041758A NO 20041758 A NO20041758 A NO 20041758A NO 20041758 L NO20041758 L NO 20041758L
Authority
NO
Norway
Prior art keywords
telmiseartan
sodium salt
crystalline sodium
angiotensin antagonist
angiotensin
Prior art date
Application number
NO20041758A
Other languages
English (en)
Other versions
NO326465B1 (no
Inventor
Kai Donsbach
Irmagard Hof
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20041758(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20041758L publication Critical patent/NO20041758L/no
Publication of NO326465B1 publication Critical patent/NO326465B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20041758A 2001-10-31 2004-04-29 Krystallinsk natriumsalt av Telmiseartan, fremgangsmate for fremstilling av slike, farmasoytiske formuleringer innholdende slike og dets anvendelse som legemiddel NO326465B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (de) 2001-10-31 2001-10-31 Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
PCT/EP2002/011394 WO2003037876A1 (de) 2001-10-31 2002-10-11 Kristallines natriumsalz des telmisartans und dessen verwendung als angiotensin antagonist

Publications (2)

Publication Number Publication Date
NO20041758L true NO20041758L (no) 2004-04-29
NO326465B1 NO326465B1 (no) 2008-12-08

Family

ID=7704331

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041758A NO326465B1 (no) 2001-10-31 2004-04-29 Krystallinsk natriumsalt av Telmiseartan, fremgangsmate for fremstilling av slike, farmasoytiske formuleringer innholdende slike og dets anvendelse som legemiddel

Country Status (34)

Country Link
EP (1) EP1442023B1 (no)
JP (1) JP5124076B2 (no)
KR (1) KR100929502B1 (no)
CN (1) CN100509789C (no)
AR (1) AR037148A1 (no)
AT (1) ATE370125T1 (no)
AU (1) AU2002338886B2 (no)
BR (1) BR0213568A (no)
CA (1) CA2463146C (no)
CO (1) CO5580785A2 (no)
CY (1) CY1107504T1 (no)
DE (2) DE10153737A1 (no)
DK (1) DK1442023T3 (no)
EA (1) EA007596B1 (no)
EC (1) ECSP045089A (no)
ES (1) ES2291505T3 (no)
HR (1) HRP20040372A8 (no)
HU (1) HUP0402391A3 (no)
IL (2) IL161165A0 (no)
ME (1) MEP43608A (no)
MX (1) MXPA04004013A (no)
MY (1) MY129741A (no)
NO (1) NO326465B1 (no)
NZ (1) NZ532716A (no)
PE (1) PE20030629A1 (no)
PL (1) PL211462B1 (no)
PT (1) PT1442023E (no)
RS (1) RS50879B (no)
SA (1) SA02230419B1 (no)
SI (1) SI1442023T1 (no)
TW (2) TWI341200B (no)
UA (1) UA82833C2 (no)
UY (1) UY27520A1 (no)
WO (1) WO2003037876A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
CA2555294A1 (en) 2004-02-11 2005-08-25 Marina Yu Etinger Candesartan cilexetil polymorphs
MXPA06012702A (es) * 2004-05-05 2007-04-02 Teva Pharma Preparacion de candesartan cilexetil de alta pureza.
WO2006044754A2 (en) 2004-10-18 2006-04-27 Dr. Reddy's Laboratories Ltd. Process for preparing telmisartan
MX2007005348A (es) * 2004-11-03 2007-06-25 Teva Pharma Formas amorfas y polimorficas de sodio de telmisartan.
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (de) * 2008-07-29 2010-02-10 Sandoz AG Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
AU2010251194B2 (en) 2009-05-20 2016-02-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical oral telmisartan solution
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
HUE053745T2 (hu) 2011-11-25 2021-07-28 Adverio Pharma Gmbh Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában
PT3209647T (pt) 2014-10-21 2020-09-10 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
KR101872726B1 (ko) * 2016-07-28 2018-06-29 주식회사 씨트리 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
WO2020143793A1 (zh) * 2019-01-10 2020-07-16 石药集团中奇制药技术（石家庄）有限公司 杂环化合物盐及其应用
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs
AU2024276892A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
TW202541793A (zh) 2023-12-15 2025-11-01 德商百靈佳殷格翰維美迪加股份有限公司 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
ATE230263T1 (de) * 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
DE19901921C2 (de) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

Also Published As

Publication number Publication date
IL161165A0 (en) 2004-08-31
PL367477A1 (en) 2005-02-21
TWI333419B (en) 2010-11-21
HUP0402391A2 (hu) 2005-03-29
CY1107504T1 (el) 2013-03-13
TW201034664A (en) 2010-10-01
HRPK20040372B4 (hr) 2025-09-12
CO5580785A2 (es) 2005-11-30
EP1442023B1 (de) 2007-08-15
AR037148A1 (es) 2004-10-27
EP1442023A1 (de) 2004-08-04
HRP20040372A8 (hr) 2025-09-12
KR100929502B1 (ko) 2009-12-03
PE20030629A1 (es) 2003-07-14
JP5124076B2 (ja) 2013-01-23
DE50210719D1 (de) 2007-09-27
EA007596B1 (ru) 2006-12-29
ATE370125T1 (de) 2007-09-15
CN100509789C (zh) 2009-07-08
HUP0402391A3 (en) 2010-03-29
YU36304A (sh) 2006-08-17
NO326465B1 (no) 2008-12-08
IL161165A (en) 2009-12-24
ECSP045089A (es) 2004-06-28
MXPA04004013A (es) 2004-06-18
HK1073841A1 (en) 2005-10-21
HRPK20040372B3 (en) 2006-02-28
SA02230419B1 (ar) 2007-07-31
CN1578772A (zh) 2005-02-09
JP2005536445A (ja) 2005-12-02
RS50879B (sr) 2010-08-31
SI1442023T1 (sl) 2007-12-31
UA82833C2 (uk) 2008-05-26
KR20050035172A (ko) 2005-04-15
TW200300082A (en) 2003-05-16
DE10153737A1 (de) 2003-05-28
UY27520A1 (es) 2003-05-30
HRP20040372A2 (en) 2004-10-31
MEP43608A (en) 2011-02-10
EA200400479A1 (ru) 2004-10-28
PT1442023E (pt) 2007-09-17
BR0213568A (pt) 2004-09-08
DK1442023T3 (da) 2007-11-05
CA2463146A1 (en) 2003-05-08
PL211462B1 (pl) 2012-05-31
AU2002338886B2 (en) 2008-04-17
MY129741A (en) 2007-04-30
CA2463146C (en) 2011-01-25
WO2003037876A1 (de) 2003-05-08
NZ532716A (en) 2007-06-29
TWI341200B (en) 2011-05-01
ES2291505T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
DK1442023T3 (da) Krystallinsk natriumsalt af telmisartan og anvendelse af dette som angiotensinantagonist
ATE258918T1 (de) Kristallform alpha des perindopril-tert- butylaminsalzes
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DE60303751D1 (de) Echtzeitüberwachung der Formationsfrakturierung
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
NO20026010L (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
PL376575A1 (pl) Podstawione związki heterocykliczne oraz sposoby wykorzystania
FI20021262A7 (fi) Sokerien kiteytys
AU2002338886A1 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
ATE391502T1 (de) Kristalline formen von fluvastatin-natrium
PT1432685E (pt) Hidratos cristalinos de derivados de anilida do acido nicotinico e de benzoilanilida
NO20040996L (no) Nye forbindelser og sammensetninger som catepsin-inhibitorer
NO20041968L (no) Anvendelse av cystationin
PL373163A1 (en) Salt of (s)-pantoprazole and its hydrates
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
EP1558276A4 (en) FLAVIVIRIS FUSION INHIBITORS
FI20021531A0 (fi) Muurausmenetelmä
SI1408964T1 (sl) Uporaba 2- 5-(4-fluorofenil)-3-piridilmetil-aminometil -kromana in njegovih fizioloĺ ko sprejemljivih soli
EE200300567A (et) Meetod amorfse naatrium-tsilastatiini valmistamiseks
NO20044364L (no) Hydroksykarbamimidoyl-2-hydroksy-benzensulfonamidderivat-krystaller
NO20044302L (no) Krystallinsk parecoxibnatrium
DE60140529D1 (de) Feuerlöschende Zusammensetzung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees